Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

New York is the first state to address the challenges created by the Risk Adjustment program


Posted on: 13 Sep 16

NEW YORK, Sept. 12, 2016 (GLOBE NEWSWIRE) -- New York is the first state to address the challenges created by the Risk Adjustment program. In response to the forward-looking approach taken by the Department of Financial Services (DFS) on Friday, EmblemHealth’s President and CEO, Karen Ignagni, released the following statement:

"The actions by the Department of Financial Services are an important step to address the unintended consequences of the federal risk adjustment system. This proposal will help bring greater stability to the Marketplace and better protect small businesses by preserving affordable choices across the state."

About EmblemHealth
EmblemHealth, one of the nation’s largest nonprofit health plans, serves 3.1 million people who live and work across the New York tristate area. The company offers quality, affordable health benefits to consumers, employers and government purchasers as well as coverage for prescription drugs, dental and vision care. EmblemHealth utilizes a choice of quality networks to deliver personalized, coordinated care while leading the market in value-based delivery. For more information, visit EmblemHealth.com.

GlobeNewswire
globenewswire.com

Last updated on: 13/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.